Proceedings of the National Academy of Sciences · 9 October 2026 · From issue 49
IGF2BP1 in 17q-gain cooperates with MYCN to regulate purine biosynthesis and immunotherapy efficacy in neuroblastoma
In lab models, blocking one repair protein made aggressive neuroblastoma tumors respond better to immune therapy.
Jiaxu Liu, Yingzhe Fang et al.
In lab models of a childhood cancer called neuroblastoma, two genetic changes often appear together and make the disease worse. A protein called IGF2BP1 teams up with a cancer driving gene to fuel a building block factory that makes DNA raw materials. Blocking a related repair protein made tumor cells more visible to the immune system. This made immune based drugs work better in lab models.
Shows a lab demonstrated path to boost immune attack on aggressive neuroblastoma cells.
Lab and cell models only, no human trial data yet.
Integrity screen: passed (3 checks) Checked 12 October 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Proceedings of the National Academy of Sciences). Read the source
This screen checks process signals. It does not tell you the findings are true.